Maristella Bianconi, Luca Faloppi, Michele Del Prete, Riccardo Giampieri, Alessandro Bittoni, Antonio Lopez-Beltran, Marina Scarpelli, Liang Cheng, Mario Scartozzi, Stefano Cascinu, Rodolfo Montironi
{"title":"舒尼替尼治疗晚期肾细胞癌疗效的预测因素:我们真的取得进展了吗?","authors":"Maristella Bianconi, Luca Faloppi, Michele Del Prete, Riccardo Giampieri, Alessandro Bittoni, Antonio Lopez-Beltran, Marina Scarpelli, Liang Cheng, Mario Scartozzi, Stefano Cascinu, Rodolfo Montironi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Renal cell carcinoma is an aggressive neoplasm, frequently diagnosed incidentally in an advanced stage (local or metastatic). Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, mainly directed against the angiogenic pathway. Sunitinib is largely used in first-line treatment, but response varies widely among patients. Thus, there is an urgent need to find predictive factors able to determine whether or not a patient would respond to treatment, thereby avoiding unnecessary toxicities. In this report we review the literature focusing on clinical, pathological, and molecular predictive factors currently being studied and more promising to enter clinical practice.</p>","PeriodicalId":55517,"journal":{"name":"Analytical and Quantitative Cytopathology and Histopathology","volume":"37 1","pages":"3-13"},"PeriodicalIF":0.1000,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward?\",\"authors\":\"Maristella Bianconi, Luca Faloppi, Michele Del Prete, Riccardo Giampieri, Alessandro Bittoni, Antonio Lopez-Beltran, Marina Scarpelli, Liang Cheng, Mario Scartozzi, Stefano Cascinu, Rodolfo Montironi\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Renal cell carcinoma is an aggressive neoplasm, frequently diagnosed incidentally in an advanced stage (local or metastatic). Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, mainly directed against the angiogenic pathway. Sunitinib is largely used in first-line treatment, but response varies widely among patients. Thus, there is an urgent need to find predictive factors able to determine whether or not a patient would respond to treatment, thereby avoiding unnecessary toxicities. In this report we review the literature focusing on clinical, pathological, and molecular predictive factors currently being studied and more promising to enter clinical practice.</p>\",\"PeriodicalId\":55517,\"journal\":{\"name\":\"Analytical and Quantitative Cytopathology and Histopathology\",\"volume\":\"37 1\",\"pages\":\"3-13\"},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2015-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Analytical and Quantitative Cytopathology and Histopathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Analytical and Quantitative Cytopathology and Histopathology","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward?
Renal cell carcinoma is an aggressive neoplasm, frequently diagnosed incidentally in an advanced stage (local or metastatic). Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, mainly directed against the angiogenic pathway. Sunitinib is largely used in first-line treatment, but response varies widely among patients. Thus, there is an urgent need to find predictive factors able to determine whether or not a patient would respond to treatment, thereby avoiding unnecessary toxicities. In this report we review the literature focusing on clinical, pathological, and molecular predictive factors currently being studied and more promising to enter clinical practice.